

APPENDIX 1

Submissions and additional information received by the Committee

Submissions

- 1** Bayer HealthCare Pharmaceuticals
- 2** CanSpeak
- 3** Ms Kerry Drinkwater
- 4** Mr John Dowling
- 5** Mr David Prestridge
- 6** Mr Paul Hobson
- 7** Mr Andrew Warden
- 8** Mr Doug Meiklejohn
- 9** Ms Jan Darby
- 10** Mr George Curr
- 11** Mrs Karen Cowley
- 12** Mr Janis Kinne
- 13** Mr Peter Carr
- 14** Name Withheld
- 15** Mr Peter Renwick
- 16** Haematology Society of Australia and New Zealand
- 17** Mr Michael Cochrane
- 18** Mr Leroy Lai
- 19** Mr Jason Noble
- 20** Capt. Michael Cottell
- 21** Mr John Perz
- 22** Mr Mark Usher

- 23 Mr Ken Young
- 24 Mr John Betts
- 25 Ms Lee McKerracher
- 26 Professor John Zalcborg OAM
- 27 Mr Michael Armessen
- 28 Urey Lau
- 29 Name Withheld
- 30 Ms Lorraine Hoskin
- 31 Ms Fanny Lai
- 32 Mr Luke Boyd
- 33 Mrs Ligia Matic
- 34 Mr Geoffrey Olsson
- 35 Mr Michael East
- 36 Ms Leah Graeve
- 37 Ms Lara Chapman
- 38 Ms Michelle East
- 39 Miss Natasha Jauncey
- 40 Name Withheld
- 41 Mr Peter Brown
- 42 Ms Jennifer Shepherd
- 43 Mr Neville Black
- 44 Ms Tracy Magiatis
- 45 Ms Kym Short
- 46 Specialised Therapeutics Australia
- 47 Mr Trevor Olsson
- 48 Ms Pauline Grant
- 49 Cancer Voices Australia (plus a supplementary submission)

- 50 Mr Glenn Stoddart
- 51 Mr Allen Sibley
- 52 Ms Ashley Jeffery
- 53 Cancer Drugs Alliance
- 54 Mr Russell Broadbent
- 55 John Logan Cancer Treatment Foundation
- 56 Mr Tony Maxwell (plus three attachments)
- 57 Mr Allan Davies
- 58 Mr Alan Barlee
- 59 Mr Patrick Coughlan
- 60 Name Withheld
- 61 Mr Trevor Brown
- 62 Mr and Mrs Paul and Maureen Thompson
- 63 Mr Alan Kearon
- 64 Brain Tumour Alliance Australia Inc
- 65 Ms Lillian Leigh
- 66 Dr Janet Wale
- 67 Name Withheld
- 68 Mr Bob Schmidt
- 69 Ms Janet Humphery
- 70 Mr and Mrs Peter and Eileen Brown
- 71 Rev Dr Noel Preston AM
- 72 Ms Chantal Tierney
- 73 Name Withheld
- 74 Mr and Mrs David and Pauline Armstrong
- 75 Ms Anita Rollinson
- 76 Mr John Shaw

- 77 Mrs Maureen Meiklejohn
- 78 Confidential
- 79 Mrs Jill Delahoy
- 80 Ms Linda Wilson
- 81 Mr Darren Smith
- 82 Ms Gail McGuinness
- 83 Palliative Care Australia
- 84 Ms Helen Scalzo
- 85 Ms Jennifer Litsas
- 86 Ms Louise Manoe
- 87 Novartis Oncology
- 88 CanSpeak Queensland
- 89 Confidential
- 90 Breast Cancer Network Australia
- 91 Mr Duncan Mitchell
- 92 Rare Cancers Australia (plus an attachment)
- 93 Ms Josie Muller
- 94 Mrs Claire Murnane
- 95 Ms Sharon Ryan
- 96 Ms Elizabeth Olsson
- 97 Ms Marion Davis
- 98 Ms Maureen Austin
- 99 Ms Tereena Cocks
- 100 Mr Damian Lech
- 101 Ms Catherine Arena
- 102 Name Withheld
- 103 Geelong Prostate Support Group

-
- 104** Mr Scott Beyer
- 105** Advanced Prostate Cancer Support Group
- 106** Mr Jim Marshall
- 107** Name Withheld
- 108** Medical Oncology Group of Australia
- 109** AbbVie
- 110** Mrs Joanne Wills
- 111** Mr Michael Cook
- 112** Society of Hospital Pharmacists of Australia
- 113** Ms Lesley Royle
- 114** Roche
- 115** Name Withheld
- 116** Melanoma Patients Australia
- 117** Private Cancer Physicians of Australia Limited
- 118** Merck Serono Australia
- 119** Amgen Australia Pty Ltd
- 120** Merck Sharp and Dohme Australia (plus two attachments and a supplementary submission)
- 121** Pfizer Australia
- 122** Takeda Pharmaceuticals Australia
- 123** Leukaemia Foundation of Australia
- 124** Mr and Mrs Gerald and Suzanne Whitty
- 125** Link Healthcare
- 126** GI Cancer Institute Consumer Advisory Panel
- 127** Mr Eric South
- 128** Dr Agnes Vitry
- 129** Mrs Laura Carrington

- 130** The Unicorn Foundation
- 131** Gilead Sciences (plus a supplementary submission)
- 132** IVD Australia
- 133** Mr Terry Crook
- 134** Mr Ray Chilton
- 135** Dr Ian Musgrave
- 136** Ms Cindy Davenport
- 137** Ovarian Cancer Australia
- 138** Bristol-Myers Squibb
- 139** Ms Jolanda Visser
- 140** Janssen-Cilag Pty Ltd (plus a supplementary submission)
- 141** Ms Cathy Watt
- 142** Medicines Australia (plus two attachments and a supplementary submission)
- 143** Mrs Karen van Gorp
- 144** Australian Melanoma Consumer Alliance
- 145** Cancer Council Australia and Clinical Oncology Society of Australia
- 146** CanTeen
- 147** Novo Nordisk
- 148** Mr Wallace Donald
- 149** Bowel Cancer Australia
- 150** Cancer Voices South Australia
- 151** Cancer Action Victoria Inc
- 152** Australian and New Zealand Children's Haematology Oncology Group (plus a supplementary submission)
- 153** Dr James McIntosh
- 154** Name Withheld
- 155** Ms Roselyn King

- 156** Mrs Lesley Hondrakis
- 157** Ms Caeleigh Hancock
- 158** Hepatitis Australia
- 159** Australasian Leukaemia and Lymphoma Group
- 160** Ms Tess Hemeter
- 161** Mr Rob Royle
- 162** Ms Monique Prior
- 163** Ms Kelly Hill
- 164** Mr Malcolm Trim
- 165** Ms Fiona Jewell
- 166** Genomics For Life
- 167** Lymphoma Australia
- 168** Mr Graham Evans
- 169** Mr Richard Harrison
- 170** Mr David Simcox
- 171** Ms Kim Watts
- 172** Mr Mark Haspels
- 173** Ms Teresa Cilona
- 174** Mr Jim Gruchy
- 175** Ms Nathalie Cook
- 176** Pharmaceutical Society of Australia
- 177** Dr Scott Chapman
- 178** Ms Allison McMaster
- 179** Ms Kate McIntosh
- 180** Ms Jane Casey
- 181** Mrs Anna Hickey
- 182** Mr Trevor Stenner

- 183** Australian Institute of Health and Welfare
- 184** Meni Stefanovski
- 185** Ms Deb Twomey
- 186** Ms Irene Ormsby
- 187** Cure Brain Cancer Foundation
- 188** Tasmanian Government Department of Health and Human Services
- 189** Mr Laurance Cook
- 190** Consumers Health Forum of Australia
- 191** Eli Lilly Australia
- 192** The Kids' Cancer Project
- 193** Generic Medicines Industry Association
- 194** Ms Elizabeth Smith
- 195** Mr Temple Kehoe
- 196** Pharmaceutical Benefits Advisory Committee
- 197** Australian Government Department of Health
- 198** Mr Peter Jones
- 199** Australian Melanoma Research Foundation
- 200** Name Withheld
- 201** Mr Matthew Storey
- 202** Name Withheld
- 203** Cancer Council Victoria's Clinical Network
- 204** Mr Brian Pound
- 205** Ms Angela Willett

Additional Information

- 1 Pharmacy tax invoice, from Chris Brugger, received 20 April 2015
- 2 Stakeholder perceptions study, by GA Research, from Rare Cancers Australia, received 22 April 2015
- 3 Information in relation to access to medicines for rare cancer patients in Australia, from Rare Cancers Australia, received 16 September 2015

Answers to Questions on Notice

- 1 Answers to Questions taken on Notice during 20 April public hearing, received from Advanced Prostate Cancer Support Groups, 24 April 2015
- 2 Answers to Questions taken on Notice during 20 April public hearing, received from Roche, 6 May 2015
- 3 Answers to Questions taken on Notice during 20 April public hearing, received from Australian Melanoma Research Foundation, 15 May 2015
- 4 Answers to Questions taken on Notice during 20 April public hearing, received from Cancer Drugs Alliance, 19 May 2015
- 5 Answers to Questions taken on Notice during 20 April public hearing, received from Novartis Oncology, 21 May 2015
- 6 Answers to Questions taken on Notice during 20 April public hearing, received from Ovarian Cancer Australia, 22 May 2015
- 7 Answers to Questions taken on Notice during 20 April public hearing, received from Clinical Oncology Society of Australia, 22 May 2015
- 8 Answers to Questions taken on Notice during 20 April public hearing, received from Leukaemia Foundation of Australia, 22 May 2015
- 9 Answers to Questions taken on Notice during 20 April public hearing, received from Society of Hospital Pharmacists of Australia, 22 May 2015
- 10 Answers to Questions taken on Notice during 20 April public hearing, received from Australian and New Zealand Children's Haematology and Oncology Group, 22 May 2015

- 11 Answers to Questions taken on Notice during 20 April public hearing, received from CanTeen, 22 May 2015
- 12 Answers to Questions taken on Notice during 20 April public hearing, received from Private Cancer Physicians of Australia, 22 May 2015
- 13 Answers to Questions taken on Notice during 20 April public hearing, received from Merck Sharp and Dohme, 24 May 2015
- 14 Answers to Questions taken on Notice during 20 April public hearing, received from Medicines Australia, 25 May 2015
- 15 Answers to Questions taken on Notice during 20 April public hearing, received from Unicorn Foundation, 25 May 2015
- 16 Answers to Questions taken on Notice during 20 April public hearing, received from Pharmaceutical Benefits Advisory Committee, 28 May 2015
- 17 Answers to Questions taken on Notice during 20 April public hearing, received from Merck Sharp and Dohme, 28 May 2015
- 18 Answers to Written Questions on Notice, received from NHS England, 16 June 2015
- 19 Answers to Questions taken on Notice during 20 April public hearing, received from Department of Health, 5 August 2015

Tabled Documents

- 1 Picture, tabled by Naomi Brugger, at Canberra public hearing 20 April 2015